Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of Ravagalimab in Moderately to Severely Active Primary Sjogren's Syndrome
2019-003131-31Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome (SS) comparing Ravagalimab with Placebo (2 arms). Primary endpoint: Change from baseline in ESSDAI. Started Dec 2019; status: terminated.
02
Drugs
ravagalimab
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on 2019-003131-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003131-31.